EW Edwards Lifesciences
Wonderful regulatory-moat medtech, but price already bakes in ~25% growth versus a realistic ~10%.
The business
Edwards Lifesciences makes surgical and transcatheter heart valves (TAVR, mitral/tricuspid) and hemodynamic monitoring systems, selling to hospitals and cardiac surgeons/cardiologists who implant devices in a recurring, high-clinical-stakes replacement cycle.
Quality gate · 80/100
Moat & management
| Moat | wide moat |
| Source | regulatory |
| Trajectory | stable |
| Management | excellent |
Structural heart devices require years of clinical trials, FDA approval, and physician retraining/proctoring before adoption, creating durable switching costs and regulatory barriers; Edwards has iterated TAVR platforms (Sapien) for over a decade maintaining leadership, though Medtronic, Abbott, and Boston Scientific are credible competitors in adjacent structural heart segments (mitral/tricuspid), keeping the moat from widening further.
Management has consistently reinvested heavily in R&D/clinical trials to defend TAVR leadership and expand into mitral/tricuspid, while shrinking share count (-1.5% CAGR) and maintaining a net-cash balance sheet rather than over-levering for M&A.
Owner-earnings inputs
| Owner earnings (TTM) | 1.09B |
| Owner-earnings yield | 2.3% |
| Free-cash-flow yield | 2.3% |
| Growth used (normalized) | 10.0% |
| Market-implied growth (reverse DCF) | 25.0% |
| Terminal growth | 3.0% |
| Discount rate (hurdle) | 9.0% |
Projected owner earnings
| Yr | Owner earnings | Growth | PV |
|---|---|---|---|
| 1 | 1.10B | 10.0% | 1.01B |
| 2 | 1.20B | 9.2% | 1.01B |
| 3 | 1.31B | 8.4% | 1.01B |
| 4 | 1.41B | 7.7% | 996.15M |
| 5 | 1.50B | 6.9% | 976.86M |
| 6 | 1.59B | 6.1% | 950.96M |
| 7 | 1.68B | 5.3% | 918.98M |
| 8 | 1.76B | 4.6% | 881.50M |
| 9 | 1.82B | 3.8% | 839.27M |
| 10 | 1.88B | 3.0% | 793.07M |
Key risks
- TAVR/TMTT market share erosion from Medtronic, Abbott, Boston Scientific in mitral/tricuspid
- Reimbursement or hospital capital-spending pressure slowing procedure volume growth
- Pipeline/clinical trial setbacks (e.g., in newer transcatheter mitral/tricuspid programs) delaying next growth leg
- FCF conversion (0.39) well below net income, indicating working-capital or capex intensity that could persist
Catalysts
- Continued TAVR indication expansion (younger/lower-risk patients) and international penetration
- TMTT (mitral/tricuspid) platform reaching commercial scale as a new growth pillar
- Structural heart category growth as an aging population increases valve replacement volumes
Recent news
score · 8 articles
- Edwards Lifesciences Corp (EW) Q2 2026 Earnings Call Highlights: Strong Sales Growth and ...
- Edwards Lifesciences Q2 Earnings Call Highlights
- Edwards Lifesciences (EW) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates
- Edwards Lifesciences Narrows Full-Year Sales Outlook After Second-Quarter Growth
- Edwards Stock Launches As Heart-Valve Replacements Beat On
- Edwards' Q2 Earnings on the Horizon: What's in the Cards?
- Edwards Lifesciences served $10m penalty over JC Medical acquisition violations
- FTC Says Henkel Deal Would Merge ‘Coke and Pepsi’ of Adhesives
⚠ maintenance capex ≈ min(capex, D&A), capped at FCF · Net cash 2.2B credited to value (interest stripped from owner earnings to avoid double-counting). · Price pays for ~25%/yr owner-earnings growth over 10y (reverse DCF); model credits 10%. · Rich vs our conservative value, but a quality business is not a short — stance is WAIT for a better price, not sell.